Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate CancerReportar como inadecuado

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

ISRN OncologyVolume 2012 2012, Article ID 242850, 7 pages

Clinical Study

Department of Oncology, Wayne State University and Karmanos Cancer Center, Detroit, MI 48201, USA

Division of Hematology-Oncology, Henry Ford Health System, Detroit, MI 48202, USA

Department of Medicine, Section of Oncology, John D. Dingell VA Medical Center, Detroit, MI 48201, USA

Received 18 March 2012; Accepted 9 April 2012

Academic Editors: S. Honoré and B. Luber

Copyright © 2012 Shin Ogita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction-Background. Nonmetastatic castrate resistant prostate cancer CRPC is a challenging disease state. The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients. Patients. Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy. Methods. Bevacizumab 10 mg-kg intravenously was administered every 14 days until PSA progression, development of metastasis, or unacceptable toxicity. Results. 15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months. Median baseline PSA was 27 ng-mL, and seven patients had Gleason Score ≥8. Five patients had declined in PSA during the treatment. Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months. Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively. There were three grade 3 adverse events one proteinuria and two hypertension and one pulmonary embolism. There was no treatment-related mortality. Conclusion. Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC, and investigation of novel strategies is needed.


Fuente: https://www.hindawi.com/


Documentos relacionados